Dermatology Times, May 2022 (Vol. 43. No. 5)

Vitiligo’s Emerging Drug Pipeline

May 05, 2022

Ruxolitinib cream 1.5% may soon be the first FDA-approved treatment for repigmentation of vitiligo. Experts share what dermatologists need to know regarding efficacy, safety, and cost of this topical drug.

Evaluating Job Opportunities: Financial Factors to Consider

May 03, 2022

“Given the difference in state taxes, the bottom-line difference for the physician could be in 6 figures—every year! Compounded with even a conservative growth rate, this could mean millions of dollars of difference over a career.”

New Cosmeceutical Ingredients

May 03, 2022

“Medical literature from India and the Middle East is full of reports of success in treating postinflammatory hyperpigmentation and melasma with topical tranexamic acid, but properly powered, well-controlled studies are still lacking.”

Study: How Can Digital Therapeutic Interventions Improve Symptoms of Atopic Dermatitis?

April 12, 2022

What role will digital therapeutic agents have in the coming years of atopic dermatitis treatment? It’s still being studied, but Jonathan Silverberg, MD, reviewed an interventional study that may provide key insights into what’s to come.

Optimize Off-Label Use of Biologics and New Medications

March 27, 2022

Experts explored out-of-the-box solutions for treating challenging skin and hair disorders at the American Academy of Dermatology (AAD)’s 2022 Annual Meeting held March 25 to 29, 2022, in Boston, Massachusetts.